Business
ENDRA Life Sciences Expands Pharmaceutical Partnerships with VGI Health Technology to Provide TAEUS for Patient Screening and Biomarker Measurement for Phase 2 Study
VGI’s Upcoming Phase 2 NAFLD-NASH study to incorporate ENDRA’s TAEUS technology to help drive trial efficiencies ANN ARBOR, Mich. & SYDNEY--(BUSINESS WIRE)--
About this update from Endra Life Sciences Inc.
[{"type":"text","content":"\nVGI’s Upcoming Phase 2 NAFLD-NASH study to incorporate ENDRA’s TAEUS technology to help drive trial efficiencies\n\n ANN ARBOR, Mich. & SYDNEY--(BUSINESS WIRE)--\nENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), and VGI Health Technology Limited (NSX: VTL), a clinical-stage biotechnology company specializing in developing and commercializing evidence-based nutraceuticals and pharmaceuticals, announce today the signing of a collaboration agreement to incorporate ENDRA’s proprietary TAEUS technology to support patient screening and biomarker measurement during VGI’s upcoming Phase 2 study of IVB001 in Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).\n\n\"We are delighted to partner with VGI to help advance the clinical development of IVB001. It’s clear that pharmaceutical companies and contract research organizations driving the NAFLD-NASH therapy pipeline face the same hepatic steatosis measurement challenges using MRI and liver biopsy as end-user clinicians face. By adding ENDRA’s cost-effective, non-invasive TAEUS technology to VGI’s clinical trial protocol, we expect to deliver time and cost savings through simpler, faster and non-invasive biomarker measurements of liver fat,” commented ENDRA's Chief Executive Officer Francois Michelon. “In addition, we are excited to expand and strengthen our global presence into Australia, which provides further opportunity to educate care providers and patients alike regarding the importance of detection and treatment of this condition.”\n\n“We are excited to incorporate ENDRA’s technology in our Phase 2 study of IVB001 in NAFLD-NASH,” said VGI’s Chief Executive Officer and Managing Director Glenn Tong, Ph.D. “There is enormous potential value in capturing data on the degree of hepatic steatosis and other biomarkers at the front-end, and throughout the study, to refine our understanding of systemic variables associated with NAFLD-NASH. We believe ENDRA’s TAEUS system is uniquely designed to accomplish this task for us. VGI’s focus on innovation leads us to explore new technologies like TAEUS that can drive efficiencies in the execution of our clinical studies.”\n\nIn September 2015 a Phase 1a clinical study with IVB001 met all primary endpoints including confirmation of the bioavailability of the compoun...